[Cost-effectiveness analysis of fracture liaison services in Catalonia]. / Análisis de coste-efectividad de las Unidades de Coordinación de Fracturas en Cataluña.

OBJECTIVE: To assess the cost-effectiveness of Fracture Liaison Service (FLS) compared to the standard of care for secondary prevention of fragility fractures form the perspective of the Catalan Health Service. METHODS: Cost-utility assessment through a Markov model that simulated disease progression of a patients' cohort candidates to initiate antiosteoporotic treatment after a fragility fracture. A time horizon of 10 years and a 6-month duration per cycle was established. Clinical, economics and quality of life parameters were obtained from the literature and derived from four Catalan FLS. The Catalan Health Service perspective was adopted, considering direct health costs expressed in 2022 euros. A 3% discount rate was applied on costs and outcomes. Uncertainty was assessed through multiple sensitivity analyses. RESULTS: Compared to the standard of care, FLS would promote antiosteoporotic initiation and persistence, reducing the incidence and mortality associated with subsequent fragility fractures. This incremental clinical benefit was estimated at 0.055 years and 0.112 quality-adjusted life years (QALYs) per patient. A higher cost (€1,073.79 per patient) was estimated, resulting into an incremental cost-utility ratio of €9,602.72 per QALYs gained. The sensitivity analyses performed were consistent, corroborating the robustness and conservative approach of the base-case. CONCLUSIONS: The introduction of FLS for the secondary prevention of FF would represent a cost-effective strategy from the Catalan Health Service perspective.

Perfil asistencial del paciente con osteoporosis tributario de visita de telemedicina en la era post-COVID-19 / Care profile of susceptible patients with osteoporosis by telemedicine visits in the post-COVID-19 era

Definir el perfil del paciente con osteoporosis candidato y no candidato a la asistencia en la teleconsulta de osteoporosis, en la era post-COVID-19. Propuesta de un protocolo de manejo para su seguimiento ambulatorio. Métodos: Hemos realizado una revisión bibliográfica mediante una búsqueda sistemática en las bases de datos de Pubmed.gov de la evidencia disponible de artículos en inglés y español con fecha de inclusión hasta octubre del 2020 siguiendo las recomendaciones del sistema GRADE (Grading of Recommendations, Assessment, Development and Evaluation). Base de datos cuyo objetivo es la localización y recuperación de información relevante para esta revisión de forma actualizada. Resultados: El perfil del paciente candidato a teleconsulta sería aquel paciente con historia de osteoporosis, que conoce su enfermedad, con tratamiento y que precisa de seguimiento. La COVID-19 se ha dado en un contexto en el que las principales causas de mortalidad son las enfermedades crónicas y la necesidad de protegerse frente a la transmisión. Conclusiones: Proponemos un consenso del manejo de dicho paciente, con apartados diferenciados para las distintas etapas del proceso asistencial telemático, que ayude a la toma de decisiones clínicas y que sirva de ayuda en el proceso de seguimiento y adherencia terapéutica, y, por tanto, en la optimización de recursos asistenciales. (AU)

Objetive: Define the profile of the candidate and non-candidate osteoporosis patient for assistance in osteoporosis teleconsultation, in the post-COVID-19 era. Proposal of a management protocol for outpatient follow-up. Methods: We have carried out a bibliographic review through a systematic search in the Pubmed.gov databases of the available evidence of articles in English and Spanish with an inclusion date until October 2020, following the recommendations of the GRADE system (Grading of Recommendations, Assessment, Development and Evaluation). Database is aimed at locating and accessing relevant information for this review in an updated way. Results: The profile of the patient candidate for teleconsultation would be of those who present a history of osteoporosis, previously diagnosed, with treatment and requiring follow-up. COVID-19 has occurred in a context in which the main causes of mortality are chronic diseases and the need to protect against transmission. Conclusions: We propose a consensus for managing this patient, with differentiated sections for the different stages of the telematic care process. This will help in clinical decision-making and also in the process of follow-up and therapeutic adherence and, therefore, in optimal use of healthcare resources. (AU)

The Vibrio cholerae hlyC gene encodes a protein that is related to lipases of pseudomonas species.

The nucleotide sequence of the Vibrio cholerae N16961 hlyC gene was determined. The hlyC gene encompasses 513 nucleotides that are predicted to encode a 171-amino acid protein with a calculated molecular weight of 18.2 kDa. The predicted HlyC protein contains a region that is 93.5% similar to the substrate-binding/catalytic domain of the Pseudomonas species triacylglycerol acylhydrolase (lipase). The proposed catalytic serine residue is also conserved in the HlyC protein. The contribution of the putative HlyC lipase to the physiology of V. cholerae is currently under investigation.

Adhesions to manufacturer's trademark on the surface of a posterior chamber lens.

A case is reported in which posterior synechiae to the manufacturer's trademark on the surface of a Shearing intraocular lens were noted ten days after the implantation of the lens. After a short course of low-concentration miotic therapy, the adhesions were broken. We concluded that irregularities on the surface of the lens, such as a manufacturer's trademark, provide a focus for synechiae. We suggest that intraocular lens manufacturers refrain from providing such identification on their products.